NEW YORK, Jan. 20, 2016 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of MannKind Corporation ("Mannkind" or the "Company") (NASDAQ: MNKD), concerning whether the board has breached its fiduciary duties to shareholders.
On January 5, 2016, MannKind disclosed the termination of its license and collaboration agreement with sanofi-aventis U.S. LLC ("Sanofi") for the product, Afrezza. The same day, Bloomberg quoted a Sanofi spokesman as saying that Sanofi terminated the agreement due to low level of prescriptions. StreetInsider reported that Cox said that prescription levels of Afrezza never even met modest expectations.
On this news, Mannkind stock fell nearly 50% to close at $0.75 per share on January 5, 2015.
Our investigation concerns whether the board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own Mannkind shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq. Benjamin I. Sachs-Michaels, Esq. Harwood Feffer LLP 488 Madison Avenue New York, New York 10022 Phone Numbers: (877) 935-7400 (212)935-7400 Email: email@example.com Website: http://www.hfesq.com Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP